Strategic Partnerships Affibody maintains active collaborations with global biopharma and healthcare companies (including AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum), presenting outbound sales opportunities to expand licensing, co-development, and commercialization deals for its Affibody molecules and Albumod platform.

Clinical Pipeline With three clinical stage programs targeting psoriasis, B-cell driven autoimmune diseases, and a diagnostic imaging program for metastatic breast cancer, there are multiple touchpoints for outreach to pharma partners seeking early to mid-stage assets, as well as diagnostic imaging collaborations.

Therapeutic Focus Emphasize Affibody's next generation biotherapeutics and proprietary platforms to potential customers seeking innovative modalities beyond traditional monoclonal antibodies, highlighting opportunities to license or co-develop novel drugs using Affibody molecules and Albumod technology.

Executive Access Recent leadership appointment of a Chief Business Officer signals strategic emphasis on business development and partnerships, suggesting favorable timing for outreach to discuss collaboration, licensing terms, and deal structures.

Commercial Readiness Existing revenue is modest but company has $50M in funding and ongoing commercial relationships, indicating a capable partner for early-stage asset development and potential collaborative revenue-sharing models as programs advance toward clinical milestones.